FDA Inspection 1142661 — Blueprint Medicines Corporation
The FDA completed an inspection of Blueprint Medicines Corporation on May 5, 2021 in Cambridge, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 5, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cambridge, MA (United States)
Additional Details
Sponsor, Contract Research Organization